Catalyst
Slingshot members are tracking this event:
New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMY |
|
|
||||
Additional Information
Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients who had relapsed or progressed after auto-HSCT and subsequent brentuximab vedotin, as assessed by an independent radiologic review committee
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 10, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nivolumab, Opdivo, Hodgkin Lymphoma, Brentuximab Vedotin
